Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2021

View Archived Issues

Bile acid sequestrant SAR-442357 improves experimental type 2 diabetes and comorbidities

C3aR is a potential therapeutic target in vascular cognitive impairment

Jacobio Pharmaceuticals and AbbVie initiate phase I/II study of JAB-3312

Enrollment commences in phase I study of recombinant IAP SYN-020

APX-3330 enters phase II development for diabetic retinopathy

FDA approves new expanded indication for Anavip

Zydus reports positive phase III data for PegiHep in patients with COVID-19

First patient dosed in a phase II study of ensovibep for the treatment of COVID-19

Antibodies could make things worse in neurodegeneration

Myeloid cells differ in primary and recurrent glioblastoma

Unnatural Products describes MDM2/4 bispecific inhibitor UNP-1797

U.S. researchers patent protein kinase inhibitors

Roche divulges new TLR antagonists

Cadila Healthcare presents new NLRP3 inflammasome inhibitors

Japanese investigators identify P2X4 receptor antagonists

Forevertek Biotechnology and ProMab Biotechnologies divulge MAbs against SLAM family member 7

Oryzon announces preclinical collaboration with Seaver Autism Center at Mount Sinai

Dosing begins in phase I study of the bispecific antibody TJ-L-14B/ABL-503

Pfizer's oral SARS-CoV-2 main protease inhibitor PF-07321332 enters phase I

Recognify Life Sciences initiates phase IIa trial of RL-007 in CIAS

An efficient target deconvolution approach based on highly parallelized CRISPR/Cas9 genome editing

MfpA protein acts a T-segment mimic to protect DNA gyrase from fluoroquinolones

Landos' IND for omilancor in eosinophilic esophagitis cleared in U.S.

Study shows neurological or psychiatric diagnoses for 1 in 3 COVID-19 survivors

Bridge Biotherapeutics begins phase I/II trial of BBT-176 in EGFR-mutant NSCLC with C797S

AzurRx starts phase II RESERVOIR study in patients with COVID-19 GI infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...